D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 104 Citations 48,495 405 World Ranking 4116 National Ranking 2333

Overview

What is he best known for?

The fields of study he is best known for:

  • Schizophrenia
  • Internal medicine
  • Cognition

His scientific interests lie mostly in Psychiatry, Schizophrenia, Cognition, Clinical psychology and Psychosis. His Positive and Negative Syndrome Scale study in the realm of Schizophrenia interacts with subjects such as Context. His Cognition study incorporates themes from Schizophrenia, Research design and Psychometrics.

The various areas that Richard S.E. Keefe examines in his Clinical psychology study include Longitudinal study, Clinical trial, Neuropsychology, Mental health and Cohort. His studies deal with areas such as Vigilance, Cognitive disorder, Intelligence quotient and Agnosia as well as Psychosis. Richard S.E. Keefe combines subjects such as Quetiapine, Risperidone and First episode, Internal medicine with his study of Olanzapine.

His most cited work include:

  • Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia (4568 citations)
  • The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity (1401 citations)
  • Persistent cannabis users show neuropsychological decline from childhood to midlife (937 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Psychiatry, Cognition, Schizophrenia, Clinical psychology and Psychosis. Richard S.E. Keefe has researched Cognition in several fields, including Schizophrenia, Clinical trial and Developmental psychology, Psychometrics. In his research on the topic of Schizophrenia, Placebo is strongly related with Internal medicine.

His Clinical psychology study combines topics in areas such as Cognitive remediation therapy, Cognitive skill, Effects of sleep deprivation on cognitive performance, Cognitive test and Schizotypal personality disorder. His research integrates issues of Perception and Audiology in his study of Psychosis. His work investigates the relationship between Olanzapine and topics such as Risperidone that intersect with problems in Quetiapine and Perphenazine.

He most often published in these fields:

  • Psychiatry (48.41%)
  • Cognition (51.17%)
  • Schizophrenia (53.29%)

What were the highlights of his more recent work (between 2016-2021)?

  • Cognition (51.17%)
  • Schizophrenia (53.29%)
  • Clinical psychology (45.44%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Cognition, Schizophrenia, Clinical psychology, Psychosis and Schizophrenia. His Cognition study contributes to a more complete understanding of Psychiatry. His work on Bipolar disorder as part of general Psychiatry study is frequently linked to Genome-wide association study, bridging the gap between disciplines.

The concepts of his Schizophrenia study are interwoven with issues in Neurocognitive, Placebo and Internal medicine. His Clinical psychology research integrates issues from Outpatient clinic, Cognitive test, Anxiety, Treatment response and Cohort. His biological study spans a wide range of topics, including Psychotherapist, Association, Emotion recognition and Audiology.

Between 2016 and 2021, his most popular works were:

  • The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms (49 citations)
  • Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory (43 citations)
  • A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia (33 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Schizophrenia
  • Cognition

Richard S.E. Keefe mainly focuses on Cognition, Schizophrenia, Clinical psychology, Psychiatry and Clinical trial. His Cognition research is multidisciplinary, relying on both Physical therapy, Psychopathology and Cognitive decline. His study in the field of Positive and Negative Syndrome Scale also crosses realms of Degree.

His Clinical psychology research includes themes of Young adult, Neurocognitive, Consistency and Outpatient clinic. His Connectomics research extends to the thematically linked field of Psychiatry. His work in Clinical trial covers topics such as Cognitive test which are related to areas like Standard score, Audiology, Test and Cognitive Assessment System.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Jeffrey A. Lieberman;T. Scott Stroup;Joseph Patrick McEvoy;Joseph Patrick McEvoy;Marvin S. Swartz.
The New England Journal of Medicine (2005)

7121 Citations

The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity

Keith H. Nuechterlein;Michael F. Green;Robert S. Kern;Lyle E. Baade.
American Journal of Psychiatry (2008)

2140 Citations

Persistent cannabis users show neuropsychological decline from childhood to midlife

Madeline H. Meier;Avshalom Caspi;Antony Ambler;Antony Ambler;Hona Lee Harrington.
Proceedings of the National Academy of Sciences of the United States of America (2012)

1712 Citations

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

Richard S.E Keefe;Terry E Goldberg;Philip D Harvey;James M Gold.
Schizophrenia Research (2004)

1395 Citations

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

Richard S.E. Keefe;Robert M. Bilder;Sonia M. Davis;Philip D. Harvey.
Archives of General Psychiatry (2007)

1287 Citations

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

Joseph Patrick McEvoy;Jeffrey A. Lieberman;T. Scott Stroup;Sonia M. Davis.
American Journal of Psychiatry (2006)

1141 Citations

Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria

Michael F. Green;Keith H. Nuechterlein;James M. Gold;M Deanna.
Biological Psychiatry (2004)

1051 Citations

The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis

Richard S.E. Keefe;Susan G. Silva;Diana O. Perkins;Jeffrey A. Lieberman.
Schizophrenia Bulletin (1999)

975 Citations

Antipsychotic drug effects on brain morphology in first-episode psychosis

Jeffrey A. Lieberman;Jeffrey A. Lieberman;Gary D. Tollefson;Cecil Charles;Robert Zipursky.
Archives of General Psychiatry (2005)

927 Citations

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.

Philip D. Harvey;Richard S.E. Keefe.
American Journal of Psychiatry (2001)

848 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Richard S.E. Keefe

Philip D. Harvey

Philip D. Harvey

University of Miami

Publications: 356

Matcheri S. Keshavan

Matcheri S. Keshavan

Beth Israel Deaconess Medical Center

Publications: 257

Gary Remington

Gary Remington

Centre for Addiction and Mental Health

Publications: 180

Larry J. Seidman

Larry J. Seidman

Beth Israel Deaconess Medical Center

Publications: 173

Michael F. Green

Michael F. Green

University of California, Los Angeles

Publications: 155

Ole A. Andreassen

Ole A. Andreassen

Oslo University Hospital

Publications: 143

René S. Kahn

René S. Kahn

Icahn School of Medicine at Mount Sinai

Publications: 132

Jeffrey A. Lieberman

Jeffrey A. Lieberman

Columbia University

Publications: 131

Christoph U. Correll

Christoph U. Correll

Charité - University Medicine Berlin

Publications: 129

John A. Sweeney

John A. Sweeney

University of Cincinnati

Publications: 128

John M. Kane

John M. Kane

Zucker Hillside Hospital

Publications: 127

Larry J. Siever

Larry J. Siever

Icahn School of Medicine at Mount Sinai

Publications: 127

Herbert Y. Meltzer

Herbert Y. Meltzer

Northwestern University

Publications: 123

Jim van Os

Jim van Os

University Medical Center Utrecht

Publications: 117

Christopher R. Bowie

Christopher R. Bowie

Queen's University

Publications: 109

Merete Nordentoft

Merete Nordentoft

University of Copenhagen

Publications: 109

Trending Scientists

Vittorio Murino

Vittorio Murino

University of Verona

Devi Parikh

Devi Parikh

Facebook (United States)

Yisheng Zhong

Yisheng Zhong

Tsinghua University

J.Y. Richard Liew

J.Y. Richard Liew

National University of Singapore

Maryvonne Hervieu

Maryvonne Hervieu

Université de Caen Normandie

Zhi Dang

Zhi Dang

South China University of Technology

Daniel T. Chiu

Daniel T. Chiu

University of Washington

Xiaojing Hao

Xiaojing Hao

University of New South Wales

Carlos A. Quesada

Carlos A. Quesada

National Institute of Amazonian Research

Gretta T. Pecl

Gretta T. Pecl

University of Tasmania

Hannah M. Buchanan-Smith

Hannah M. Buchanan-Smith

University of Stirling

Joseph Arul

Joseph Arul

Université Laval

Timothy R. Green

Timothy R. Green

Agricultural Research Service

Alistair M. S. Smith

Alistair M. S. Smith

University of Idaho

Samuel S.-H. Wang

Samuel S.-H. Wang

Princeton University

Diana S. Woodruff-Pak

Diana S. Woodruff-Pak

Temple University

Something went wrong. Please try again later.